Maximilian Kullmann
Overview
Explore the profile of Maximilian Kullmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vakalopoulos A, Basting D, Brechmann M, Teller H, Boultadakis Arapinis M, Straub A, et al.
J Med Chem
. 2024 Oct;
67(21):19165-19187.
PMID: 39463278
Autonomic disbalance, i.e., sympathetic overactivation and parasympathetic withdrawal, is a causal driver of disease progression in heart failure. While sympatholytic drugs are established treatments, no drug therapy restoring vagal control...
2.
Stadler C, Ellinghaus U, Fischer L, Bahr-Mahmud H, Rao M, Lindemann C, et al.
Sci Transl Med
. 2024 May;
16(748):eadl2720.
PMID: 38776391
We present the preclinical pharmacology of BNT142, a lipid nanoparticle (LNP)-formulated RNA (RNA-LNP) encoding a T cell-engaging bispecific antibody that monovalently binds the T cell marker CD3 and bivalently binds...
3.
He M, Zhu S, Cannon J, Christensen J, Duggal R, Gunduz M, et al.
Drug Metab Dispos
. 2023 Aug;
51(11):1436-1450.
PMID: 37591731
Therapeutic peptides (TPeps) have expanded from the initial endogenous peptides to complex modified peptides through medicinal chemistry efforts for almost a century. Different from small molecules and large proteins, the...
4.
Le Roux A, Blaise E, Boudreault P, Comeau C, Doucet A, Giarrusso M, et al.
J Med Chem
. 2020 May;
63(13):6774-6783.
PMID: 32453569
We herein report the first thorough analysis of the structure-permeability relationship of semipeptidic macrocycles. In total, 47 macrocycles were synthesized using a hybrid solid-phase/solution strategy, and then their passive and...
5.
Kotz S, Kullmann M, Kalayda G, Dyballa-Rukes N, Jaehde U, Metzger S
Electrophoresis
. 2018 Apr;
39(12):1488-1496.
PMID: 29676816
Intracellular binding of cisplatin to proteins has been associated with acquired resistance to chemotherapy. In our previous study we established an analytical method for the identification of intracellular cisplatin-binding proteins....
6.
Mondritzki T, Steinbach S, Boehme P, Hoffmann J, Kullmann M, Schock-Kusch D, et al.
J Pharmacol Toxicol Methods
. 2017 Nov;
90:7-12.
PMID: 29100965
Introduction: Quantitative assessment of renal function by measurement of glomerular filtration rate (GFR) is an important part of safety and efficacy evaluation in preclinical drug development. Existing methods are often...
7.
Kalayda G, Kullmann M, Galanski M, Gollos S
J Biol Inorg Chem
. 2017 Oct;
22(8):1295-1304.
PMID: 29043454
Oxaliplatin is the backbone of chemotherapy for advanced colorectal cancer and undergoes clinical trials for treatment of other tumour entities. However, acquired resistance is a major hurdle. Confocal microscopy is...
8.
Kullmann M, Kotz S, Hellwig M, Kalayda G, Metzger S, Jaehde U
Int J Clin Pharmacol Ther
. 2015 Nov;
53(12):1038-40.
PMID: 26521923
No abstract available.
9.
Kullmann M, Kalayda G, Hellwig M, Kotz S, Hilger R, Metzger S, et al.
J Inorg Biochem
. 2015 Sep;
153:247-252.
PMID: 26364260
Intracellular binding of cisplatin to non-DNA partners, such as proteins, has received increasing attention as an additional mode of action and as mechanism of resistance. We investigated two cisplatin-interacting isoforms...
10.
Kotz S, Kullmann M, Crone B, Kalayda G, Jaehde U, Metzger S
Electrophoresis
. 2015 Aug;
36(21-22):2811-2819.
PMID: 26250553
Cisplatin is one of the most widely used anticancer agents, but a major problem for successful chemotherapy is the development of drug resistance of tumor cells against cisplatin. Resistance to...